Clinical use in COVID-19
JAK-inhibitors are under investigation for their potential role in
regulating the overactive signalling in the JAK-STAT pathway seen during
cytokine storm in critically ill COVID-19 patients. Baricitinib with its
potential to inhibit clathrin-mediated endocytosis and its ability to
ameliorate associated chronic inflammation in interferonopathies is
expected to show promising results in ongoing clinical trials of
COVID-19 (154,155).